Newsletter

Regeneron Pharmacueticals and Teva Pharmaceutical Report Positive Topline Phase 3 Clinical Trial Results of Fasinumab

On August 16, Regeneron Pharmaceuticals, Inc. (REGN) and Teva Pharmaceutical Industries Ltd. (TEVA) announced positive topline results from a Phase 3 clinical trial of Fasinumbab in patients with chronic pain from osteoarthritis of the knee or hip. After 16 weeks, the study met both co-primary endpoints as well as all key secondary endpoints. Patients treated […]

Read more...

Strongbridge Biopharma Reports Positive Results in Phase 3 SONICS Study of RECORLEV

On August 8, Strongbridge Biopharma plc (SBBP) announced top-line results from its Phase 3 SONICS study evaluating RECORLEVTM(levoketoconazole) for the treatment of endogenous Cushing’s syndrome. The open-label, single-arm SONICS study produced statistically significant results of its pre-specified primary endpoint. At six months, 30% of patients demonstrated a normalization rate of Urinary Free Cortisol. Sonal alerted […]

Read more...

Horizon Pharma Reports Second Quarter Earnings and Increases Annual Guidance

Horizon Pharma plc (HZNP) reported its second-quarter 2018 earnings on August 8. Net sales increased by 4.6% due to strong growth for its orphan and rheumatology medicines. The company increased its annual adjusted EBITDA guidance to between $400 million and $420 million. Horizon Pharma has realigned its operating structure into two segments so that it […]

Read more...

Fortune Brands Home & Security Increases Annual Earnings Outlook on Strong Second-Quarter Sales Results

Fortune Brands Home & Security, Inc. (FBHS) announced its second-quarter 2018 earnings on July 26. Sales increased 5% year-over-year to $1.4 billion. The company increased its guidance for annual EPS before charges/gains to between $3.62 and $3.72.   Sonal issued an alert to subscribers at 4:05 pm. The next trade was for $53.97 at 4:06 […]

Read more...

Check Point Software Technologies Expands Current Share Repurchase Program

Check Point Software Technologies Ltd. (CHKP) announced on July 25 that the company’s Board of Directors authorized a major expansion of the current share repurchase program. The updated repurchase plan is effective immediately and increases the quarterly repurchase 30% to $325 million in outstanding shares. The overall repurchase plan increased 100% to a total of […]

Read more...

Fidelity National Financial Announces New Stock Repurchase Program

On July 17, Fidelity National Financial, Inc. (FNF) announced that the company’s Board of Directors approved a new stock repurchase program. The new repurchase program replaces the previous stock repurchase program, which expires on July 31. The company repurchased a total of 10.6 million shares of stock with the previous program. The new stock repurchase […]

Read more...

Reata Pharmaceuticals Reports Positive Phase 2 Results From Two Clinical Trials

On July 23, Reata Pharmaceuticals, Inc. (RETA) announced results from two Phase 2 clinical trials of bardoxolone in patients with chronic kidney disease. The one-year results for the Phase 2 portion of CARDINAL, a study of bardoxolone in patients with chronic kidney disease due to Alport syndrome, found that patients had no drug-related negative side […]

Read more...

Capstone Turbine Announces Contract Renewals Totaling 4.4MW

Capstone Turbine Corporation (CPST) announced on July 11 that the company has secured nine separate Factory Protection Plan (FPP) aftermarket long-term service contract renewals from a major U.S. oil and gas producer. The contracts cover a total of 4.4 MWs. Capstone Turbine is the world’s leading clean technology manufacturer of microturbine energy systems.   Sonal […]

Read more...